CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Mayo Clinic
Incyte Corporation
Dren Bio
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
AVM Biotechnology Inc
Ohio State University Comprehensive Cancer Center
Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Arovella Therapeutics Ltd
University of Colorado, Denver
Bristol-Myers Squibb
The First Affiliated Hospital of Soochow University
Eastern Cooperative Oncology Group
Medical College of Wisconsin
AstraZeneca
AvenCell Therapeutics, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Vironexis Biotherapeutics Inc.
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
Nurix Therapeutics, Inc.
Thomas Jefferson University
Fate Therapeutics
Cellectar Biosciences, Inc.
Center for International Blood and Marrow Transplant Research
Center for International Blood and Marrow Transplant Research
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Sellas Life Sciences Group
National Institutes of Health Clinical Center (CC)
University of Oklahoma
Memorial Sloan Kettering Cancer Center
Allogene Therapeutics
BeOne Medicines
University of Chicago
Baylor College of Medicine
Penn State University
Gamida Cell ltd
Ossium Health, Inc.